(Nasdaq: MIRM), a leading rare disease company, today announced completion of enrollment in the Phase 3 AZURE-1 study and completion of screening in the Phase 3 AZURE-4 study, both evaluating ...
New research shows that deltaviruses can sneak into cells by hitchhiking inside other viruses, highlighting a previously ...
Mirum Pharmaceuticals has entered a definitive agreement to acquire Bluejay Therapeutics — a deal that, if finalized, would add brelovitug, a phase 3-stage monoclonal antibody for chronic hepatitis ...
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Week 48 endpoint analysis from the Company’s Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) ...
Hepatitis delta virus (HDV), a bloodborne infection that is transmitted through infected blood or other bodily fluids, was recently designated as a Group 1 carcinogen by the International Agency for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results